Card-20(22)-enolid, 3-((O-2,6-Di-deoxy-4-O-methyl-beta-D-ribo-hexo-pyranosyl-(1=>4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-L-(1=>4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydro-xy-, (3 beta, 5 beta, 12 beta)-

Methyldigoxin

HCID 443946CAS 30685-43-9

Teilstruktursuche Ähnliche Strukturen suchen

Grundinformationen

Standard-SMILES: CO[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)O[C@@H]1C
InChIKey: IYJMSDVSVHDVGT-PEQKVOOWSA-N
Summenformel: C42H66O14
Durchschnittliche Molmasse: 795 g/mol
Monoisotopische Masse: 794,44525679

Überblick

Metildigoxin is a cardenolide glycoside.

Namen und Bezeichner

Bevorzugter Name: Methyldigoxin
IUPAC: 3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-3-[(2R,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-methoxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
Lokaler Name: Card-20(22)-enolid, 3-((O-2,6-Di-deoxy-4-O-methyl-beta-D-ribo-hexo-pyranosyl-(1=>4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-L-(1=>4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydro-xy-, (3 beta, 5 beta, 12 beta)-
Englischer Name: Metildigoxin
Summenformel: C42H66O14
Molmasse: 794.97

Namen und Synonyme

metildigoxinMethyldigoxin30685-43-9MetildigoxinaMetildigoxineMetildigoxinumDigoxin, 4'''-O-methyl-DTXSID0023294Methyldigoxin, betaI7GG1YUC5VDTXCID0032943-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-3-[(2R,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-methoxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one

Weitere Namen anzeigen

b-MethyldigoxinMetildigoxin RSβ-Methyl Digoxin-β-Methyl Digoxinbeta-Methyldigoxin4'''-Methyldigoxin4'''-b-Methyldigoxin

metildigossina3-((3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-3-((2R,4S,5S,6R)-4-hydroxy-5-((2S,4S,5S,6R)-4-hydroxy-5-((2S,4S,5S,6R)-4-hydroxy-5-methoxy-6-methyloxan-2-yl)oxy-6-methyloxan-2-yl)oxy-6-methyloxan-2-yl)oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta(a)phenanthren-17-yl)-2H-furan-5-oneRefChem:8187634'''-BETA-METHYLDIGOXINC01AA08250-292-0MEDIGOXINLanitop

Datenbank-Bezeichner

CAS: 30685-43-9
PubChem CID: 443946
DTXSID: DTXSID0023294
ChEMBL: CHEMBL1697843
ChEBI: CHEBI:135885
UNII: I7GG1YUC5V
EC Number: 250-292-0
Nikkaji: J4.091F

Eigenschaften

Berechnete Struktureigenschaften

XLogP: 1,8
Polarare Oberfläche (TPSA): 192 Å²
H-Brücken-Donoren: 5
H-Brücken-Akzeptoren: 14
Frei drehbare Bindungen: 8
Schwere Atome: 56
Formalladung: 0
Komplexität: 1.460

Experimentelle und physikochemische Eigenschaften

LogP1.73

Physikochemische Eigenschaften

Schmelzpunkt: 200 · 200-202°C (dec.)
Siedepunkt: 668.38 °C · 668.38°C (rough estimate)
Dichte: 1.102 · 1.1020 (rough estimate)
Brechungsindex: 1.613 · 1.6130 (estimate)
storage temp.: Hygroscopic, Refrigerator, Under Inert Atmosphere
Löslichkeit: DMSO (Sparingly), Methanol (Slightly)
pka: 13.5 · 13.50±0.70(Predicted)
Aggregatzustand: Solid
Farbe: White to Off-White
Stabilität: Hygroscopic

Sicherheit und Regulatorisches

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H300 (50%): Fatal if swallowed [Danger Acute toxicity, oral]

P260, P261, P264, P264+P265, P270, P271, P273, P280, P284, P301+P316, P304+P340, P305+P351+P338, P316, P319, P320, P321, P330, P337+P317, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Hazard Classes and CategoriesAcute Tox. 2 (50%)

Sicherheitsdaten

Toxizität: LD50 in rats, mice (mg/kg): 4.8, 4.9 i.v.; 6.2, 4.8 i.p.; 8.3, 7.8 orally (Czerwek)

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

C01AA08

C - Cardiovascular system

QC - Cardiovascular system

MeSH Pharmacological Classification · 3 Einträge

Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.

Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE).

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.